Effective prison-based treatment and linkage to care after release

[...]in Australia, there is a disproportionately high HCV seroprevalence among people in prison, reaching up to 50% among those who inject drugs.2 WHO has prioritised the elimination of HCV as a public health threat by 2030,3 and the prison setting must be used to engage prisoners living with HCV in...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2019-11, Vol.19 (11), p.1171-1171
Main Authors: Papaluca, Timothy J, Tambakis, George, Iser, David, Thompson, Alexander J
Format: Article
Language:English
Subjects:
Health risks
Imprisonment
Infectious diseases
Prisoners
Prisons
Public health
Serology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]in Australia, there is a disproportionately high HCV seroprevalence among people in prison, reaching up to 50% among those who inject drugs.2 WHO has prioritised the elimination of HCV as a public health threat by 2030,3 and the prison setting must be used to engage prisoners living with HCV in care to achieve these targets. In this setting, we recently described a nurse-led model of care for HCV treatment in prison that was safe and achieved cure rates greater than 95% among prisoners.4 These data endorse Tavoschi and colleagues' recommendations and show that system-wide prison programmes are feasible and effective. AJT has received investigator-initiated research funding to their institution from Gilead, Merck Sharpe & Dohme, AbbVie, and Bristol-Myers Squibb, and has been an advisory board member for Gilead, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Eisai and Bayer.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(19)30536-5